



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/19, 31/215</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/62507</b>  <b>(43) International Publication Date:</b> 9 December 1999 (09.12.99)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(21) International Application Number:</b> PCT/GB99/01684  <b>(22) International Filing Date:</b> 27 May 1999 (27.05.99)   <b>(30) Priority Data:</b>  <div style="display: flex; justify-content: space-between;"> <div>9811784.9</div> <div>2 June 1998 (02.06.98)</div> <div>GB</div> </div> <div style="display: flex; justify-content: space-between;"> <div>9827834.4</div> <div>17 December 1998 (17.12.98)</div> <div>GB</div> </div>   <b>(71) Applicant (for all designated States except US):</b>            ARTHROMICS PLC [GB/GB]; Peter House, 8th floor, St. Peter's Square, Manchester M1 5BH (GB).   <b>(72) Inventors; and</b>  <b>(75) Inventors/Applicants (for US only):</b> BILLINGHAM, Michael, Edward, John [GB/GB]; St. Michaels, South Road, Alresford, Hants SO24 9HR (GB). FERNIHOUGH, Janet, Katherine [GB/GB]; The Garden Flat, 39 Livingstone Road, Oldfield Park, Bath BA2 3PH (GB).   <b>(74) Agents:</b> KOLKER, Peter, Leigh et al.; Martin A. Hay &amp; Co., 13 Queen Victoria Street, Macclesfield, Cheshire SK11 6LP (GB).         </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).   <b>Published</b>  <i>With international search report.</i> </td> </tr> </table>			<b>(21) International Application Number:</b> PCT/GB99/01684 <b>(22) International Filing Date:</b> 27 May 1999 (27.05.99)  <b>(30) Priority Data:</b> <div style="display: flex; justify-content: space-between;"> <div>9811784.9</div> <div>2 June 1998 (02.06.98)</div> <div>GB</div> </div> <div style="display: flex; justify-content: space-between;"> <div>9827834.4</div> <div>17 December 1998 (17.12.98)</div> <div>GB</div> </div> <b>(71) Applicant (for all designated States except US):</b> ARTHROMICS PLC [GB/GB]; Peter House, 8th floor, St. Peter's Square, Manchester M1 5BH (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BILLINGHAM, Michael, Edward, John [GB/GB]; St. Michaels, South Road, Alresford, Hants SO24 9HR (GB). FERNIHOUGH, Janet, Katherine [GB/GB]; The Garden Flat, 39 Livingstone Road, Oldfield Park, Bath BA2 3PH (GB).  <b>(74) Agents:</b> KOLKER, Peter, Leigh et al.; Martin A. Hay & Co., 13 Queen Victoria Street, Macclesfield, Cheshire SK11 6LP (GB).	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(21) International Application Number:</b> PCT/GB99/01684 <b>(22) International Filing Date:</b> 27 May 1999 (27.05.99)  <b>(30) Priority Data:</b> <div style="display: flex; justify-content: space-between;"> <div>9811784.9</div> <div>2 June 1998 (02.06.98)</div> <div>GB</div> </div> <div style="display: flex; justify-content: space-between;"> <div>9827834.4</div> <div>17 December 1998 (17.12.98)</div> <div>GB</div> </div> <b>(71) Applicant (for all designated States except US):</b> ARTHROMICS PLC [GB/GB]; Peter House, 8th floor, St. Peter's Square, Manchester M1 5BH (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BILLINGHAM, Michael, Edward, John [GB/GB]; St. Michaels, South Road, Alresford, Hants SO24 9HR (GB). FERNIHOUGH, Janet, Katherine [GB/GB]; The Garden Flat, 39 Livingstone Road, Oldfield Park, Bath BA2 3PH (GB).  <b>(74) Agents:</b> KOLKER, Peter, Leigh et al.; Martin A. Hay & Co., 13 Queen Victoria Street, Macclesfield, Cheshire SK11 6LP (GB).	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>			
<b>(54) Title:</b> COMPOUNDS WHICH INTERACT WITH THE THYROID HORMONE RECEPTOR FOR THE TREATMENT OF FIBROTIC DISEASE				
<div style="text-align: center;">(I)</div>				
<b>(57) Abstract</b>  <p>A method of alleviating fibrotic disease by regulating tissue destructive proteolytic enzyme production in the presence of thyroid receptor binding but in the substantial absence of substantive corticosteroid and androgen receptor binding by administration of an effective amount of at least one compound having formula (I), in which X stands for the oxygen or sulphur atom or for the imino (-NH-) or sulphonyl (-SO<sub>2</sub>-) radical, Y stands for a direct linkage, or for the oxygen or sulphur atom or for the sulphonyl (-SO<sub>2</sub>-) radical or for the radical of the formula -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>1</sup> and R<sup>2</sup> which may be the same or different are hydrogen, alkyl or aryl radicals as hereinafter described, ring B may be optionally substituted by one or more substituents selected from halogen atoms and alkyl and aryl radicals, n is an integer having the value 0 or 1, and esters, amides and salts thereof, and the use of at least one compound having structure (I) in the preparation of a medicament in such a method.</p>				

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# COMPOUNDS WHICH INTERACT WITH THE THYROID HORMONE RECEPTOR FOR THE TREATMENT OF FIBROTIC DISEASE

This invention relates to fibrotic diseases.

There are many fibrotic diseases in the human. These are sometimes referred to as chronic connective tissue diseases, and include degradative and proliferative conditions. They include, for example, deterioration of the joints in arthritis, deformation of vessel walls in arteriosclerosis, accelerated cardiovascular problems associated with diabetes, lung fibrosis and cirrhosis of the liver. These fibrotic diseases are generally considered and studied as separate and different problems. However, it is possible that common pathways exist in all these fibrotic diseases. Indeed, corticosteroids are used in the treatment of many of these diseases to relieve symptoms and prevent associated tissue destruction and scarring; however, the use of corticosteroids is associated with dose and treatment duration side-effects which limit the usefulness of this type of compound.

Some fibrotic diseases are particularly distressing, such as, for example, those involving deterioration of cartilage and bone in the joint. Amelioration of such diseases is a particularly difficult target for the pharmaceutical industry. These conditions are often accompanied by distressing levels of pain and gradual impairment of structural body function and movement. An added difficulty in attempting to find a satisfactory cure or improvement is that joint disease appears to be largely species specific. Therefore, research into joint disease in man is made more difficult in that animal models may not be appropriate.

In mankind, joint disease is generally progressive and affects all ages, but is particularly prevalent in middle and old age. Quality of life of the patient is severely reduced as the level of pain and reduction in mobility increase. Treatments hitherto have, therefore, been directed at manifestations of the disease or malfunction which are comparatively less difficult to treat. In rheumatoid arthritis, these include

symptom-modifying anti-rheumatic drugs (so-called SMARD) for the relief of pain and decrease in inflammation at the joint or in the synovial membrane, such as, for example, non-steroidal anti-inflammatory drugs (so-called NSAID). Some drugs are said to be disease modifying (so-called DMARD), such as, for example, non-cytotoxics such as anti-malarials, gold, sulphasalazine, D-penicillamine, and cytotoxics such as cyclophosphamide and chlorambucil. However, such drug treatments are often associated with unpleasant or undesirable side effects, which limit their application and utility. A new category of anti-rheumatic drugs, Disease Controlling Anti-Rheumatic Drugs, (so-called DCARD) has been proposed to describe drugs that effectively control the destructive processes but as yet no marketed anti-rheumatic drugs merit this classification, although corticosteroids have some inhibitory effect on the articular damage at the low doses that can be tolerated for long term treatment.

However, consideration of the above fibrotic diseases as a class having a common pathway may prove valuable in attempting to invent new treatments.

It is known that corticosteroids can regulate gene transcription by binding to their specific receptor which is one member of the steroid receptor super-family (Physiology of the steroid-thyroid hormone nuclear receptor superfamily. Williams GR, Franklyn JA. Baillière's Clinical Endocrinology and Metabolism Vol 8 No 2 pp241-266 1994). This super-family includes the glucocorticoid, oestrogen, progesterone, androgen, thyroid hormone, Vitamin D and retinoic acid receptors. Such receptors are responsible for the regulation of many genes including those encoding tissue destructive proteolytic enzymes, for example, metalloproteinases (sometimes referred to as MMPs). One such MMP is collagenase 1. Corticosteroids interact specifically with the corticoid receptor which then binds to the promoters of the genes. This liganded corticosteroid receptor represses activation of the collagenase gene by modulating the activity of transcription factor AP-1 (activating protein 1, heterodimer of c-fos and c-jun proteins; reviewed by Cato and Wade BioEssays Vol 18 No 5 pp371-378 1996). The liganded steroid receptor thus

modulates production of protein destructive enzymes, thereby reducing degradation of joint tissues such as cartilage and bone.


Many of the members of the superfamily of steroid receptors can modulate tissue destructive proteolytic enzyme production when liganded with the natural hormone. However, use of the natural hormone at pharmacological levels is associated with severe side effects due to their biological activity in many physiological systems. Corticosteroids effectively inhibit proteolytic enzyme production at the transcriptional level, through modulation of AP1, but the problem with corticosteroids is that they have additional transactivation effects on genes that lead to side effects, such as bone osteoporosis, diminishment of the immune response and water retention. Some of these side effects can be life threatening. Therefore, such inhibition or modulation in the substantial absence of the above hitherto undesirable associated side effects would represent a major therapeutic advance.

These undesirable additional transactivation effects are surprisingly substantially avoided in accordance with the present invention. It has been found that the use of the compounds described below have substantially no transactivation properties and do not transrepress body defence mechanisms signalled by immune hormones such as the cytokines, IL1 and TNF and the early response transcription factor NF $\kappa$ B (Mukaida N et al, J Biol Chem, 269, 13289-13295, 1994). The compounds below, and their associated pharmaceutical compositions, are not likely, therefore, to compromise the immune system, which is one of the one of the major problems associated with the use of corticosteroids. This is a surprising finding and clearly separates this class of molecule from the conventional steroid hormones.

It has been found that compounds (I) hereinafter described are able to regulate MMP gene activation, but surprisingly not through occupation of either the corticosteroid receptor or the androgen receptor. Therefore, surprisingly compounds (I) appear to regulate MMP gene activation through a different receptor and hence compounds (I) can thereby substantially prevent transcription of MMP, including collagenase 1.

Indeed, it has been further found that compounds (I) acts through occupation of the thyroid hormone receptor. Herein lies the basis of the present invention.

Thus according to the present invention, a method is provided of alleviating fibrotic disease by regulating tissue destructive proteolytic enzyme production in the presence of thyroid receptor binding, but in the substantial absence of substantive corticosteroid and androgen receptor binding. This is effected by administration of an effective amount of at least one compound having the formula (I)



(I)


in which X stands for the oxygen or sulphur atom or for the imino (-NH-) or sulphonyl (-SO<sub>2</sub>-) radical, Y stands for a direct linkage, or for the oxygen or sulphur atom or for the sulphonyl (-SO<sub>2</sub>-) radical or for the radical of the formula -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>1</sup> and R<sup>2</sup> which may be the same or different are hydrogen, alkyl or aryl radicals as hereinafter described, ring B may be optionally substituted by one or more substituents selected from halogen atoms and alkyl and aryl radicals, n is an integer having the value 0 or 1, and esters, amides and salts thereof.

In the compounds having the formula (I), R<sup>1</sup> and R<sup>2</sup> may be the same or different and preferably R<sup>1</sup> is selected from hydrogen or 1-4C alkyl, and R<sup>2</sup> from hydrogen, 1-4C alkyl or phenyl (which may be optionally substituted with at least one halogen atom, for example, chlorine, bromine), and R<sup>1</sup> and R<sup>2</sup> may be joined together to form a cycloalkyl ring (for example, cyclohexyl); the ring B may be optionally contain one or more substituents selected from halogen atoms and 1-4C alkyl. Most preferably, the 1-4C alkyl radicals are methyl or ethyl, and the halogen atom is chlorine.

Esters of compound (I) may be useful in the present invention. Such esters are preferably derived from alcohols having the formula  $R^3-OH$ , where  $R^3$  is preferably 1-4C alkyl, most preferably methyl or ethyl. Salts of compound (I) include alkali metal and alkaline earth salts, and include magnesium, aluminium, bismuth, ammonium, and preferably sodium, potassium and calcium. Where the compound (I) contains a strongly basic substituent, acid addition salts thereof, such as the hydrochloride, are comprehended.

Compounds having the formula (I), in which  $n$  is 1, and  $R^1$  and  $R^2$  which may be the same or different are hydrogen or alkyl radicals, are described in United Kingdom patent specification 1140748, the disclosure of which is incorporated herein. Such compounds are considered to be useful in the treatment or prophylaxis in humans and animals of such diseases as coronary artery disease and atherosclerosis. This is because they are said to reduce the concentration of cholesterol and/or triglycerides in the blood serum and the level of fibrinogen in blood plasma of rats. They are also said to possess anti-inflammatory activity in rats, and are, therefore, considered to be useful in the treatment of inflammatory signs and symptoms such as rheumatoid arthritis in man; further work has shown that such compounds have substantially no anti-inflammatory properties (Billingham MEJ and Rushton A, Anti-inflammatory and Anti-arthritic Drugs, Vol III, Edited by. KD Rainsford, 31-63, 1985, CRC Press)). A particularly preferred compound,


1-[4-(4-chlorophenyl)benzyloxy]-1-methylpropionic acid, has the formula (II)



(II)


European patent specification 0 037 698, the disclosure of which is incorporated herein, describes processes for the production of compounds having the formula (I) in

which n takes the value 1, Y is a direct link and  $R^1$  and  $R^2$  which may be the same or different are hydrogen or (1-4C) alkyl. A preferred compound has the formula (III).



(III)

United Kingdom patent specification 860303, the disclosure of which is incorporated herein, describes compounds having the formula (I) in which n takes the value 0. A preferred compound has the formula (IV) and is known as clofibrate.



(IV)

According to the present invention a method of modifying fibrotic disease in warm blooded animals is provided which comprises administering the animal an effective amount of at least one compound having the formula (I). In a further embodiment of the present invention a pharmaceutical composition is provided containing at least one compound having the formula (I) for the structural modification of fibrotic tissue in a warm blooded animal.

In accordance with the present invention, many fibrotic and proliferative conditions are considered to gain benefit from treatment with the pharmaceutical composition. These include, for example, rheumatoid arthritis, psoriatic arthritis and psoriasis itself,



the loosening of prosthetic joints, atherosclerosis of cardiac and coronary vessels and large arteries, the complications of diabetes, lung fibrosis, liver cirrhosis, systemic sclerosis, muscular dystrophy.

In order to be useful in the treatment of the above conditions in accordance with the present invention, the above compounds may be administered as a pharmaceutical composition by any suitable route, but preferably orally, as, for example, tablets, capsules, suspension, emulsions, powders, syrups, elixirs. They may be administered as suppositories. The pharmaceutical compositions may be formulated to include any pharmaceutically acceptable excipient and may be prepared by any suitable method known on the art, such as those described in any of the above patent specifications. The compositions should preferably be administered to ensure that the patient receives between 0.01g and 0.5g of active ingredient per day; the composition containing suitably between 0.01g and 0.5g of active ingredient.

The invention is illustrated with reference to the following experimental information

Two plasmid constructs were introduced by standard calcium phosphate precipitation of DNA followed by glycerol shock (Ausubel FM, Brent R, Kingston DD, Moore JG et al Current protocols in molecular biology 1994 Greene Publishing Associates/Wiley-Interscience, New York, NY) using a transformed African Green Monkey kidney cell line (CV1) (Schneikert J, Peterziel H, Defossez P-A, Klocker H, de Launoit Y and Cato ACB Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. Journal of Biological Chemistry. Vol 271(39) (pp 23907-23913), 1996).

#### Experiment 1

This experiment was intended to show reduction in MMP promoter activity. Accordingly, the following two plasmids were included into CV1 cells described above –

- (a) Either of GR1 or pSG5ARF containing glucocorticoid or androgen receptor (AR) respectively, both at 2ug per  $5 \times 10^5$  cells, driven by the Rous sarcoma virus promoter, and
- (b) a plasmid containing the -73/+63 portion of the collagenase I promoter linked to luciferase gene at 8ug per  $5 \times 10^5$  cells.

These cells were stimulated using TPA (12-O- tetradecanoylphorbol-13-acetate) at 75ng/ml, which enhanced the activity of the collagenase promoter. The stimulation increased luciferase production, which was measured by luminescence after addition of the luciferase substrate (luciferin) and co-factors.

The blank represented the inclusion of these two plasmids alone with little endogenous activation of collagenase. Addition of TPA stimulated the activity of this promoter region, resulting in a high level of luciferase production which is eventually seen as an enhancement in fluorescence (Y-axis). Both dihydroxytestosterone (DHT) at  $10^{-7}$ M and dexamethazone (Dex) at  $10^{-7}$ M were able to down regulate this activation through their respective receptors. CPII was compound II above, clobuzarit. "Empty" indicated the results when neither GR1 or AR receptors were present. The results are presented in Table 1.

Table 1

	Empty		GR1		AR	
	Raw counts	%control	Raw counts	%control	Raw counts	%control
Blank	2399	100	12842	100	2668	100
CPII	1882	78	6151	48	1374	51
TPA	5407	225	57519	448	11639	436
TPA + CPII	2747	115	39968	311	5986	224
TPA + DHT					3711	139
TPA + Dex			10981	86		

The above results are presented graphically in Figures 1a and 1b. From the results in Table 1, it is shown that Compound II was also, in addition to DHT or Dex, able to down regulate collagenase I activation, and also to inhibit partially the background level of collagenase promoter activity. The level of this reduction which is achieved

by the use of Compound II in both stimulated and unstimulated conditions is similar, when expressed as ratio of luciferase counts seen without inclusion of this molecule, over observable counts when Compound II is included. This suggests that Compound II does not require the presence of either receptor in order to exert its action. This is further supported by the observation that Compound II is able to reduce the level of both TPA stimulated and unstimulated collagenase I (MMP) promoter activity in the absence of either receptor (Empty).

## Experiment 2

This experiment was intended to investigate the activation of androgen and corticosteroid receptors by compound I.

The CV1 cells described above were transfected with the following two plasmids –

- (a) PGL3MMTV plasmid, containing a transcription site which is activated by the androgen and glucocorticoid receptor, linked to the luciferase gene at 9ug per  $5 \times 10^5$  cells, and
- (b) either one of the plasmids GR1 or pSG5ARFin, containing glucocorticoid or androgen receptor (AR) respectively, under the control of constitutively active promoters, both at 2ug per  $5 \times 10^5$  cells.

The blank represented the inclusion of these two plasmids alone, resulting in the absence of receptor activity. Inclusion of dihydroxytestosterone (DHT) at  $10^{-7}$ M or dexamethazone (Dex) at  $10^{-7}$ M to the culture medium enabled the receptor to stimulate the transcription of the promoter region linked to luciferase which was eventually seen as an enhancement in fluorescence (Y-axis). CPII was compound II above, clobuzarit, which was used at  $10^{-7}$ M.

Table 2

	AR	
	Raw counts	%control
Blank	4637	100
DHT	1731765	37347

CPII	33130	714
DHT + CPII	1232241	26574
	GR1	
	Raw counts	%control
Blank	3569	100
Dex	619085	17346
CPII	3272	92
Dex+ CPII	748249	20965

The above results are presented graphically in Figures 2a and 2b. From the results in Table 2, it is shown that Compound II shows negligible activity to activate the same mechanism as that produced by the addition of the two steroids DHT and Dex.

### Experiment 3

This experiment was intended to show the effect of compounds I on a mediator of the immune response, nuclear factor -  $\kappa$ B (NF- $\kappa$ B).

The following two plasmids were included into CV1 cells described above—

- (a) GR1 as described above at 2ug per  $5 \times 10^5$  cells, and
- (b) a plasmid designated 3-EnhTK-Luc (at 0.5ug per  $5 \times 10^5$  cells) which

contains a transcription site that is activated by NF $\kappa$ B. The cells themselves are capable of synthesising this protein and hence it is not necessary to transfect this as well.

The blank represented the inclusion of these two plasmids alone; the relatively high value was caused by (i) the high level of serum in the culture, and (ii) the associated stress that the cells underwent during the transcription process – both of which upregulate NF $\kappa$ B. There was also a related relatively low activation of TNF (at 4ng/ml) above a serum containing blank in the experiment. TNF was tumour necrosis factor alpha.

Table 3

	Raw counts	%control
Blank	59538	100
CPII	75812	127
TNF	82579	139
TNF + CPII	135886	228
TNF + Dex	18525	31

The above results are presented in Figure 3. The results show that Compound II shows little variation from the background value, indicating that it is not able to upregulate transcriptional activity by NF $\kappa$ B. The lack of inhibitory effect of Compound II on NF $\kappa$ B transcription is in contrast to the marked effect of Dex, showing that Compound II does not act as an anti-inflammatory agent, so supporting the earlier clinical data. Also, from the lack of substantive stimulation, it can also be inferred that Compound II, in contrast to DEX, does not interfere with immune response signalling.

#### Experiment 4

These experiments were intended to identify the receptor through which compounds I might be acting to block collagenase promoter activity.

Transfection procedure hereinbefore described with CV1 cells was repeated using MCF-7 mammary breast cancer cells derived from pleural effusion from a breast cancer patient. Additionally, each experiment included transfection of a plasmid (at 8 $\mu$ g per  $5 \times 10^5$  cells) containing the -517/+63 section of the collagenase (MMP-1) promoter linked to the luciferase gene. TPA was used as above to stimulate activity of the collagenase promoter resulting in luciferase production. Compound II or 3,3,5-triiodo-L-thyronine (T3) was included (both at  $10^{-8}$ M), the latter being a known ligand for the thyroid hormone receptor.

A series of three experiments was then carried out.

Experiment 4.1. As MCF-7 cells express endogenous thyroid hormone receptors, only the collagenase promoter plasmid ( at 8ug per  $5 \times 10^5$  cells) was transfected into the MCF-7 cells.

The results are shown in Table 4.1.

Table 4.1

	Raw Counts	% Control
Blank	12575	100
CPII	6029	47.9
TPA	147665	1174.3
TPA + T3	428062	3404.1
TPA + CPII	352376	2802.2

The results in Table 4.1, presented graphically in Figure 4.1, show that in MCF-7 cells, both thyroid hormone and Compound II are able further to enhance TPA stimulation of luciferase production.

Experiment 4.2. The procedure of Experiment 4.1 was repeated except that a second plasmid, containing 662bp antisense construct for the thyroid receptor (at 8ug per  $5 \times 10^5$  cells) was additionally transfected.

The results are shown in Table 4.2.

Table 4.2

	Raw Counts	% Control
Blank	1458	100
CPII	2379	163.2
TPA	4975	341.2
TPA + T3	19911	1365.6
TPA + CPII	8716	597.8

The results in Table 4.2, presented graphically in Figure 4.2, show that when the thyroid hormone receptor synthesis is inhibited, luciferase production via the action of T3 and compound II is substantially prevented.

Experiment 4.3. A second plasmid was introduced containing pSP71 vector (Promega) (at 2ug per  $5 \times 10^5$  cells) containing the coding sequence for the chick thyroid hormone receptor which shows high homology to the human thyroid hormone receptor, driven by the Rous sarcoma virus promoter to ensure constitutive production.

The results are shown in Table 4.3

Table 4.3

	Raw Counts	% Control
Blank	2183	100
CPII	1572	72
TPA	11528	528
TPA + T3	1604	73
TPA + CPII	4414	202

The results in Table 4.3, presented graphically in Figure 4.3, show that Compound II, as well as thyroid hormone, is able to reduce stimulated collagenase transcription.

Taken together, the results of Experiments 4.1, 4.2 and 4.3 show that compound II mimics the action of T3 which is a known ligand for the thyroid hormone receptor.

#### Experiment 5

This experiment was designed to demonstrate down-regulation of pro-MMP-1 and phosphorylation at serine 73 of c-jun, the latter of which is one half of the protein dimer AP-1, a key regulator of metalloprotease expression.

## Methods

Rheumatoid fibroblasts were cultured from synovium obtained from the knee joint of a patient with rheumatoid arthritis. Cells were cultured in monolayer with DMEM tissue culture medium (Gibco) with the inclusion of 5%v/v charcoal stripped serum in 75cm<sup>2</sup> flasks. The cells were treated for 36 hours with the addition of 10ng/ml TPA (phorbol ester) plus  $5 \times 10^{-7}$ M thyroid hormone, Compound II or Compound III. TPA and drugs were added at time zero and at 30 hours, the TPA addition ensured phosphorylation of c-jun.

After 36 hours, cells were lysed in phosphate buffered saline (PBS) containing protease inhibitors and 0.1% Triton-X-100, and then boiled for 5 minutes in non-reducing gel loading buffer. Samples of cell lysate corresponding to equal cell number were loaded onto a 12.5% SDS polyacrylamide gel, and electrophoresis using a Bio-Rad™, (Bio-Rad Laboratories, California USA) Mini Protean II cell was performed at approximately 100V for one hour.

Transfer of proteins to nitrocellulose membrane was performed using a Bio-Rad Mini Trans-Blot transfer cell.

Immunoblotting was performed using polyclonal rabbit anti-human phosphorylation specific (ser 73) c-jun (cat. No 06659, Upstate Biotechnology), or MMP-1 (cat. No. RDI-MMP1Habr, Research Diagnostics) antibodies diluted 1:1000 in Tris buffered saline + 3% fat free milk powder. Swine anti-rabbit horseradish peroxidase conjugated antibody, (cat. No. p0217, Dako) also at 1:1000 dilution was used as the secondary antibody. Chemiluminescent detection was employed using Amersham reagents according to manufacturer's instructions. Visualisation was achieved by exposing the membrane to X-ray film (Kodak) for one hour.



Results are shown in Figure 5. Left side column of the figure shows bands corresponding to phosphorylated c-jun (at serine 73), complexed with DNA, at the top of the figure. Right hand side column demonstrates a strong regulated band corresponding to pro-MMP-1 and a faint band at a lower molecular weight corresponding to active-MMP-1. Lanes 1 and 5 cells treated with TPA alone; Lanes 2 and 6 cells treated with TPA plus thyroid hormone; Lanes 3 and 7 cells treated with TPA plus Compound II; Lanes 4 and 8 cells treated with TPA plus Compound III.


Lanes 2, 3 and 4 show a lower intensity and therefore, amount of phosphorylation of c-jun, when compared to the TPA alone treated control in lane 1. Similarly, lanes 6, 7 and 8 show a lower intensity and therefore, a lower amount of pro-MMP-1, when compared to the TPA alone treated control in lane 5. Since the lower molecular weight band across lanes 5, 6, 7 and 8 corresponding to active MMP-1 is very faint, the regulation by thyroid hormone, and Compounds II and III appears to be occurring at the transcriptional level to produce a similar effect to thyroid hormone on the expression of pro-MMP-1.

#### Summary

Compound II, typical of compounds I, demonstrated steroid like properties in its ability to reduce collagenase promoter activity, although this was evident in the substantive absence of glucocorticoid or androgen receptors. Additionally, compound II did not activate a construct designed to show responsiveness to the glucocorticoid receptor. It did not enhance or block the activity of an immune system mediator, demonstrating that it does not possess anti-inflammatory properties, neither does it compromise immune response signalling. In a further experiment, the activity of compound II was identical to T3 in the absence and presence of endogenous or transfected thyroid hormone receptor. This demonstrated a common mechanism for these two molecules. The liganded thyroid hormone receptor is known to be able to down regulate collagenase promoter activity (A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors, Desbois-C; Aubert-D; Legrand-C; Pain-B; Samarut-J Cell. 1991 Nov 15; 67(4): 731-40), although the mechanism by which this occurs has not yet been elucidated.


CLAIMS

1. A method of alleviating fibrotic disease by regulating tissue destructive proteolytic enzyme production in the presence of thyroid receptor binding but in the substantial absence of substantive corticosteroid and androgen receptor binding.
2. A method as claimed in claim 1 in which the fibrotic disease is regulated by administration of an effective amount of at least one compound having the formula (I)




in which X stands for the oxygen or sulphur atom or for the imino (-NH-) or sulphonyl (-SO<sub>2</sub>-) radical, Y stands for a direct linkage, or for the oxygen or sulphur atom or for the sulphonyl (-SO<sub>2</sub>-) radical or for the radical of the formula -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>1</sup> and R<sup>2</sup> which may be the same or different are hydrogen, alkyl or aryl radicals as hereinafter described, ring B may be optionally substituted by one or more substituents selected from halogen atoms and alkyl and aryl radicals, n is an integer having the value 0 or 1, and esters, amides and salts thereof.

3. A method as claimed in claim 1 in which the fibrotic disease is regulated by administration of an effective amount of at least one compound having the formula (II)




4. A method as claimed in claim 1 in which the fibrotic disease is regulated by administration of an effective amount of at least one compound having the formula (III)



(III)

5. A method of regulating MMP gene activation in the substantial absence of occupation of either corticosteroid receptor or androgen receptor.
6. A method of regulating MMP gene activation in by the occupation of thyroid receptor.
7. A method of regulating MMP gene activation by the occupation of thyroid receptor but in the substantial absence of occupation of either corticosteroid receptor or androgen receptor.
8. A method of regulating MMP gene activation by the occupation of thyroid receptor but in the substantial absence of occupation of either corticosteroid receptor or androgen receptor by administration of an effective amount of at least one compound having the formula (I)


9. The use of a compound having the structure (I) in the preparation of a medicament for the structural modification of fibrotic tissue in a warm blooded animal by regulating tissue destructive proteolytic enzyme production in the presence of thyroid receptor binding but in the substantial absence of substantive corticosteroid and androgen receptor binding.



(I)


in which X stands for the oxygen or sulphur atom or for the imino (-NH-) or sulphonyl (-SO<sub>2</sub>-) radical, Y stands for a direct linkage, or for the oxygen or sulphur atom or for the sulphonyl (-SO<sub>2</sub>-) radical or for the radical of the formula -CR<sup>1</sup>R<sup>2</sup>-, wherein R<sup>1</sup> and R<sup>2</sup> which may be the same or different are hydrogen, alkyl or aryl radicals as hereinafter described, ring B may be optionally substituted by one or more substituents selected from halogen atoms and alkyl and aryl radicals, n is an integer having the value 0 or 1, and esters, amides and salts thereof.

10. The use as claimed in claim 4 in which the compound has the formula (II)



(II)

11. The use as claimed in claim 4 in which the compound has the formula (III)



(III)

12. The use of a compound having the formula (I) in the preparation of a medicament for the regulation of MMP gene activation in the substantial absence of occupation of either corticosteroid receptor or androgen receptor.
13. The use of a compound having the formula (I) in the preparation of a medicament for the regulation of MMP gene activation in by the occupation of thyroid receptor.
14. The use of a compound having the formula (I) in the preparation of a medicament for the regulation of MMP gene activation by the occupation of thyroid receptor but in the substantial absence of occupation of either corticosteroid receptor or androgen receptor.

Figure 1a  
Raw counts





Figure 1b  
%control

Figure 2a

Raw counts






Figure 2b

%control




Figure 3




Figure 4.1




Figure 4.2






Figure 4.3



9/9

Figure 5



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01684

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/19 A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 009 306 A (ICI PLC) 2 April 1980 (1980-04-02) page 9, line 12 - line 17; claims	1-14
X	GB 1 140 748 A (ICI PLC) cited in the application column 1, line 12 - line 30; examples 1,14	1-14
X	GB 860 303 A (ICI PLC) cited in the application column 1, line 13 - line 22; claims	1-14
A	WO 97 35195 A (EVANS ROLAND M ; FORMAN BARRY M (US); SALK INST FOR BIOLOGICAL STUD) 25 September 1997 (1997-09-25) claims	1-14
	--- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 July 1999

Date of mailing of the international search report

10/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01684

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 01430 A (LIGAND PHARM INC)  18 January 1996 (1996-01-18)  page 9, line 25 - page 10, line 4  -----</p>	1-14



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01684

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0009306	A	02-04-1980	AT 1855 T	15-12-1982
			AU 522183 B	20-05-1982
			AU 4975379 A	13-03-1980
			BE 878594 A	04-03-1980
			BE 878595 A	04-03-1980
			CA 1142542 A	08-03-1983
			CS 212244 B	26-03-1982
			CS 212245 B	26-03-1982
			DD 145747 A	07-01-1981
			DE 2934375 A	12-06-1980
			DE 2934398 A	12-06-1980
			DK 369579 A	09-03-1980
			FI 792564 A	09-03-1980
			FR 2468575 A	08-05-1981
			FR 2468574 A	08-05-1981
			GB 2031406 A, B	23-04-1980
			GR 65651 A	16-10-1980
			IE 48791 B	15-05-1985
			IT 1122501 B	23-04-1986
			JP 55038384 A	17-03-1980
			JP 55038385 A	17-03-1980
			NL 7906339 A	11-03-1980
			NL 7906554 A	11-03-1980
			PH 14631 A	12-10-1981
			PT 70146 A	01-10-1979
			SE 7907311 A	09-03-1980
			SE 437262 B	18-02-1985
			SE 7907390 A	09-03-1980
			US 4310544 A	12-01-1982
			US 4304788 A	08-12-1981
			ZA 7904088 A	27-08-1980
			ZW 15179 A	18-03-1981
<hr/>				
GB 1140748	A		BE 700110 A	18-12-1967
			CH 506467 A	30-04-1971
			DE 1618568 A	25-02-1971
			DK 117823 B	08-06-1970
			FR 8486 M	27-07-1973
			FR 1532701 A	22-11-1968
			NL 6708766 A, B	27-12-1967
			SE 343572 B	13-03-1972
			US 3549690 A	22-12-1970
			US 3658967 A	25-04-1972
<hr/>				
GB 860303	A		BE 645649 A	16-07-1964
<hr/>				
WO 9735195	A	25-09-1997	AU 2332497 A	10-10-1997
<hr/>				
WO 9601430	A	18-01-1996	AU 2957195 A	25-01-1996
			CA 2193685 A	18-01-1996
			EP 0769146 A	23-04-1997
			JP 10502454 T	03-03-1998
<hr/>				